AIM Vaccine Co., Ltd. Class H

As of June 30, 2026, AIM Vaccine Co., Ltd. Class H carries a market capitalization of 2.04B, placing it among publicly traded companies globally. Its enterprise value stands at 4.07B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

AIM Vaccine Co., Ltd. Class H's next confirmed earnings release is scheduled for April 1, 2027.

As of June 30, 2026, AIM Vaccine Co., Ltd. Class H has 1.23B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, AIM Vaccine Co., Ltd. Class H maintains a current ratio of 0.61, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, AIM Vaccine Co., Ltd. Class H's stock has declined approximately 61.96% over the past 52 weeks. The 50-day moving average sits at 1.67, while the 200-day moving average is 2.34.

As of June 30, 2026, AIM Vaccine Co., Ltd. Class H holds 211.10M in cash and equivalents against 2.05B in total debt, resulting in a net debt position of 1.83B. Total book value stands at 3.05B, with working capital of -1.39B providing operational flexibility.